GW Pharma rises on Swiss approval for Sativex

LONDON (ShareCast) – GW Pharmaceuticals (NasdaqGM:GWPH – newshas received regulatory approval in Switzerland for its treatment of spasticity due to multiple sclerosis (MS).

A full marketing authorization has been granted by the Swissmedic authorities for Sativex in the treatment of moderate to severe spasticity in patients who have not responded adequately to other anti-spasticity medications. GW Pharma’s European partner Almirall (Madrid: ALM.MC – news) will handle the commercialisation.

Chief Executive Officer Justin Gover: “This approval in Switzerland marks yet another regulatory success for Sativex, which is now approved in a total of 23 countries.”

Shares in GWP rose 9.3% to 190.13p at 14:30 on Wednesday.

Tags: , , , , , , ,